Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 19/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HCK | P08631 | 1/20 | 0.51 |
| ▸ | FGR | P09769 | 1/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.51 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21187589 | 1.00 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21178849 | 0.92 | RET (1.00) | RETNEK7 | |
| SCHEMBL21187717 | 0.90 | RET (1.00) | RETHCKNEK7 | |
| SCHEMBL30175197 | 0.90 | RET (1.00) | RETHCKNEK7 | |
| SCHEMBL21178797 | 0.90 | RET (1.00) | RETKDR | |
| SCHEMBL21187718 | 0.90 | RET (1.00) | RET | |
| SCHEMBL21178933 | 0.84 | RET (1.00) | RETKDRNEK7 | |
| SCHEMBL21178847 | 0.84 | RET (1.00) | RETKDRNEK7 | |
| SCHEMBL21178877 | 0.84 | RET (1.00) | RETKDRNEK7 | |
| SCHEMBL22604887 | 0.84 | RET (1.00) | RETKDRNEK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603374-B2 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors | RET, ROR1, FGFR3 | RET 1/4885CYP1A2 3782/4885HCK 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.